[go: up one dir, main page]

RU98114080A - BIOLOGICALLY ACTIVE ETHANAMINES OF BENZOTIAZOLONE - Google Patents

BIOLOGICALLY ACTIVE ETHANAMINES OF BENZOTIAZOLONE

Info

Publication number
RU98114080A
RU98114080A RU98114080/04A RU98114080A RU98114080A RU 98114080 A RU98114080 A RU 98114080A RU 98114080/04 A RU98114080/04 A RU 98114080/04A RU 98114080 A RU98114080 A RU 98114080A RU 98114080 A RU98114080 A RU 98114080A
Authority
RU
Russia
Prior art keywords
compound
formula
benzotiazolone
ethanamines
biologically active
Prior art date
Application number
RU98114080/04A
Other languages
Russian (ru)
Other versions
RU2177476C2 (en
Inventor
Боннерт Роджер
Браун Роджер
Кейдж Питер
Чешир Дэвид
Инс Фрэнсиз
Original Assignee
Астра Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9526511.2A external-priority patent/GB9526511D0/en
Application filed by Астра Фармасьютикалз Лтд. filed Critical Астра Фармасьютикалз Лтд.
Publication of RU98114080A publication Critical patent/RU98114080A/en
Application granted granted Critical
Publication of RU2177476C2 publication Critical patent/RU2177476C2/en

Links

Claims (7)

1. Соединение формулы I
Figure 00000001

где X обозначает нафтил; p равно 3; q равно 2; и r равно 2;
и его фармацевтически приемлемые соли.1. The compound of formula I
Figure 00000001

where X is naphthyl; p is 3; q is 2; and r is 2;
and its pharmaceutically acceptable salts. 2. Способ получения соединения формулы I, включающий селективное восстановление соединения формулы II
Figure 00000002

в которой p, q, r и X определены в п.1.2. A method of obtaining a compound of formula I, comprising the selective reduction of a compound of formula II
Figure 00000002

in which p, q, r and X are defined in claim 1. 3. Соединение формулы II
Figure 00000003

в которой p, q, r и X определены в п.1.3. The compound of formula II
Figure 00000003

in which p, q, r and X are defined in claim 1. 4. Применение соединения по п.1 в терапии. 4. The use of the compounds according to claim 1 in therapy. 5. Применение соединения по п.1 для получения лекарственного средства, применяемого для лечения обструктивного заболевания дыхательных путей, в частности, для лечения астмы или хронического бронхита. 5. The use of a compound according to claim 1 for the manufacture of a medicament used to treat obstructive airway disease, in particular for the treatment of asthma or chronic bronchitis. 6. Способ лечения заболевания дыхательных путей, отличающийся тем, что он включает введение пациенту, страдающему от такого состояния или склонному к нему, терапевтически эффективного количества соединения по п.1. 6. A method of treating a respiratory tract disease, characterized in that it comprises administering to a patient suffering from or prone to such a condition a therapeutically effective amount of a compound according to claim 1. 7. Способ лечения или профилактики глаукомы, отличающийся тем, что он включает введение пациенту, страдающему от такого состояния или склонному к нему, терапевтически эффективного количества соединения по п.1. 7. A method of treating or preventing glaucoma, characterized in that it comprises administering to a patient suffering from or prone to such a condition a therapeutically effective amount of a compound according to claim 1.
RU98114080/04A 1995-12-23 1996-12-13 Benzothiazolone ethaneamines with biological activity RU2177476C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9526511.2A GB9526511D0 (en) 1995-12-23 1995-12-23 Pharmaceutically active compounds
GB9526511.2 1995-12-23

Publications (2)

Publication Number Publication Date
RU98114080A true RU98114080A (en) 2000-06-27
RU2177476C2 RU2177476C2 (en) 2001-12-27

Family

ID=10786064

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98114080/04A RU2177476C2 (en) 1995-12-23 1996-12-13 Benzothiazolone ethaneamines with biological activity

Country Status (27)

Country Link
US (1) US5929100A (en)
EP (1) EP0918760B1 (en)
JP (1) JP2000502681A (en)
KR (1) KR19990076688A (en)
CN (1) CN1072214C (en)
AR (1) AR005008A1 (en)
AT (1) ATE209638T1 (en)
AU (1) AU704506B2 (en)
BR (1) BR9612234A (en)
CA (1) CA2238877A1 (en)
CZ (1) CZ288704B6 (en)
DE (1) DE69617472D1 (en)
EE (1) EE03440B1 (en)
GB (1) GB9526511D0 (en)
HU (1) HUP9900100A3 (en)
IL (2) IL124998A0 (en)
IS (1) IS4759A (en)
MX (1) MX9804828A (en)
NO (1) NO982927D0 (en)
NZ (1) NZ325500A (en)
PL (1) PL327475A1 (en)
RU (1) RU2177476C2 (en)
SK (1) SK82098A3 (en)
TR (1) TR199801196T2 (en)
TW (1) TW401411B (en)
WO (1) WO1997023470A1 (en)
ZA (1) ZA9610354B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009018A1 (en) * 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha BENZOTHIAZOLONE DERIVATIVES HAVING SELECTIVE β2 RECEPTOR AGONIST ACTIVITY
GB0218629D0 (en) * 2002-08-09 2002-09-18 Novartis Ag Organic compounds
AR040962A1 (en) * 2002-08-09 2005-04-27 Novartis Ag COMPOUNDS DERIVED FROM TIAZOL 1,3-2-ONA, PHARMACEUTICAL COMPOSITION AND COMPOSITE PREPARATION PROCESS
DE602004021959D1 (en) 2003-11-21 2009-08-20 Theravance Inc COMPOUNDS OF AGONISTIC EFFECT ON THE BETA2 ADRENEER RECEPTOR AND THE MUSCARIN RECIPE
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314944A (en) * 1980-08-22 1982-02-09 Smithkline Corporation 4-Aminoalkyl-7-hydroxy-2(3H)-indolones
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
GB8426200D0 (en) * 1984-10-17 1984-11-21 Glaxo Holdings Ltd Chemical compounds
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
US4554287A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones
AU4945185A (en) * 1984-11-08 1986-05-15 Syntex (U.S.A.) Inc. Dialkyl aminoethylaniline derivatives
DE3728695A1 (en) * 1987-08-25 1989-03-09 Schering Ag NEW BENZIMIDAZOLE DERIVATIVES
GB9210632D0 (en) * 1992-05-19 1992-07-01 Fisons Plc Compounds
IE914003A1 (en) * 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
US5648370A (en) * 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
GB9211172D0 (en) * 1992-05-27 1992-07-08 Fisons Plc Compounds

Similar Documents

Publication Publication Date Title
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
EP2156840A3 (en) Use of mometasone furoate for treating airway passage and lung diseases
RU99108731A (en) APPLICATION OF SIBUTRAMINE ANALOGS TO REDUCE LIPID LEVELS
RU2005108133A (en) DIPEPTIDNITRIL INHIBITORS KATEPSIN K
CA2184077A1 (en) Nasal and ocular administration of ketamine to manage pain and for detoxification
BR9609063A (en) Dinucleotides useful for the treatment of lung diseases
RU98111594A (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLURBIPROFEN
NO944018D0 (en) Treatment of macular degeneration
JP2009538327A5 (en)
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
RU98114080A (en) BIOLOGICALLY ACTIVE ETHANAMINES OF BENZOTIAZOLONE
RU99118588A (en) A NEW MEDICINE FOR INHALATION, HAVING A FILLING VOLUME DENSITY FROM 0.28 TO 0.38 G / ML, CONTAINING FORMOTEROL
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
SE0000601D0 (en) Methods to treat and diagnose respiratory disorders in sleep and agents to perform the procedure
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
EP0872246B1 (en) Drug for relieving pain and promoting the removal of calculi in urolithiasis
KR910015300A (en) Buspyron: Use for the treatment of sleep apnea
SE9801368D0 (en) New use
ATE131055T1 (en) TREATMENT OF COGNITIVE DISORDERS.
RU95112520A (en) APPLICATION 4'-IODO-4'-DEOXIDOXORUBICINE FOR THE TREATMENT OF AMYLOIDOSIS, METHOD OF TREATMENT OF AMYLOIDOSIS
WO2003045322A3 (en) Method for treating and preventing pancreatitis
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
KR910009255A (en) 2- (phenoxypropanolamino) ethoxy phenoxyacetic acid derivatives used as a therapeutic agent for hypertriglyceridemia, cholesterol, low levels of HDL disease and atherosclerosis